The COVID-19 pandemic has brought about newfound interest in the development of teledermatology, and we expect its growth to continue once the pandemic is over. While the advancement of teledermatology presents exciting opportunities to increase the efficiency of dermatology practices around the country, the question arises, will teledermatology truly improve access to patients who need the care most?
Certain cases have highlighted the potential to improve access to patients. A case documented by the University of Pennsylvania School of Medicine describes an instance where a teledermatology triage program was used by a community health clinic to diagnose Reed Syndrome, a condition that confers high likelihood to multiple hereditary malignancies.2 In community volunteer settings such as this, teledermatology demonstrates its ability to identify high-risk patients and extend appropriate care or instructions.
However, when considering the patient population on a national scale, multiple barriers are evident. In theory, it makes sense that remote care would allow practitioners to communicate with patients’ miles away, though studies suggest that telemedicine services are least used by many of the patients it originally intended to serve. A report from the Census Bureau’s 2011 Current Population Survey Computer and Internet Use Supplement surveyed over 53,000 households in the United States. It included questions specifically about telemedicine usage. Participants who utilized telemedical services the least included those with no high school diploma, low income (< $25,000), users over the age of 65, and most surprisingly, those living in rural areas.3 Additionally, African American and Hispanic households owned computers and had broadband adoption rates well below the national average, which are critical components to conducting any successful telehealth visit. Later, a study by George Washington University reviewing data of over 22,000 participants surveyed from 2013 to 2016, corroborated these results. They found that the populations who were least likely to use telemedical services included patients from low income families and rural areas.4 Also, they found that, of the insured population, patients covered by Medicare (age 65 or older) and Medicaid used telemedical services the least. Of note, patients over the age of 65 and those insured by Medicare make up a substantial proportion of the dermatology patient population.5
We highlight, from a population level, the barriers teledermatology patients face. Age, insurance status, race and ethnicity, and health literacy should all be accounted for as more dermatology practices transition to remote care. These patients should receive additional counseling to ensure they are appropriately equipped to adapt to changing practices.
Dermatologists and institutions should continue to foster awareness about the barriers faced by many patients, ensuring new advancements in the field of teledermatology do not improve practices at the expense of losing patients who need care most. Furthermore, as practices continue to adopt new telemedical platforms, more studies are needed to characterize the dermatology patient population before and after this transition, to better understand which patients are being lost to care.
- Tensen E, van der Heijden JP, Jaspers MWM, Witkamp L. Two decades of teledermatology: current status and integration in national healthcare systems. Curr Dermatol Rep. 2016;5(2):96-104. doi:10.1007/s13671-016- 0136-7
- Da Silva DM, Roth RR, Simpson CL. Teledermatology leading to an important diagnosis in an underserved clinic. Dermatol Online J. 2018;24(4). https:// pubmed.ncbi.nlm.nih.gov/29906004/. Accessed September 27, 2020.
- Exploring the Digital Nation: America’s Online Experience. https://www. ntia.doc.gov/files/ntia/publications/exploring_the_digital_nation_-_americas_ emerging_online_experience.pdf. accessed september 27, 2020.
- Park J, Erikson C, Han X, Iyer P. Are state telehealth policies associated with the use of telehealth services among underserved populations? Health Aff. 2018;37(12):2060-2068. doi:10.1377/hlthaff.2018.05101
- Lim HW, Collins SAB, Resneck JS, et al. The burden of skin disease in the United States. J Am Acad Dermatol. 2017;76(5):958-972.e2. doi:10.1016/j. jaad.2016.12.043